Clinical Trials Browser

Myeloproliferative Disorders × anagrelide × Clear all

NCT04285086 2025-08-13

SURPASS ET

Phase 3 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT03123588 2021-11-19

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Phase 2 Terminated

12 enrolled 15 charts

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT02076815 2015-07-29

TEAM-ET

Phase 3 Completed

Myeloproliferative Disorders, Thrombocythemia, Essential